Fisher & Paykel Healthcare Announces 2026 Annual Shareholders' Meeting for August 25 in Auckland with Online Access

Overview of Fisher & Paykel Healthcare's Global Reach and Product Range

Fisher & Paykel Healthcare Corporation Limited is a leading global designer, manufacturer, and marketer of medical devices specializing in acute and chronic respiratory care, surgical solutions, and obstructive sleep apnea treatments. Its products serve critical patient needs in hospital and home care settings, establishing the company as a prominent player in the respiratory care and medical device industry.

With distribution across more than 120 countries, the company has a strong international presence supporting its revenue diversification and market resilience. The 2026 Annual Shareholders' Meeting offers shareholders a chance to assess the company’s financial results and strategic direction following the fiscal year ending 31 March 2026.

Meeting Details: Date, Location, and Hybrid Attendance

The Annual Shareholders' Meeting will be held on Tuesday, 25 August 2026 at 2:00pm NZST at 15 Maurice Paykel Place, East T
01maki, Auckland, New Zealand—Fisher & Paykel Healthcare’s main manufacturing and corporate site. Visitor parking is available at the Daniell Building, with detailed directions provided for attendees.

To accommodate shareholder preferences, an online attendance option is available at www.virtualmeeting.co.nz/FPH26. Online participants can vote and submit questions during the meeting. A Virtual Meeting Guide has been prepared to assist shareholders with remote participation, enhancing accessibility for those outside New Zealand or preferring virtual attendance.

Voting Deadlines and Shareholder Eligibility

The record date to determine voting rights is 5:00pm NZST on Friday, 21 August 2026. Shareholders registered by this time may vote on the seven resolutions. Postal votes and proxy appointments must be received by 2:00pm NZST on 21 August 2026, providing a two-day buffer before the meeting.

Voting options include online submission via vote.cm.mpms.mufg.com/FPH, postal mail to MUFG Pension & Market Services, or in-person at the meeting. The Board has authorised the share registrar to receive and count postal votes. Electronic voting cards will be issued to online attendees, while paper voting cards will be provided at registration for in-person voters.

Director Election and Board Governance

Resolution 1 requests shareholder approval to elect Anna Curzon as a director of Fisher & Paykel Healthcare. This election is a significant governance decision, with explanatory notes offering background on Ms Curzon’s qualifications included in the full annual report and meeting materials.

Director elections are standard at annual meetings, reflecting the company’s commitment to Board renewal and governance standards. Shareholders may vote for, against, or abstain on this resolution, with the Board’s position detailed in the meeting documentation.

Proposed NZ$350,000 Increase in Non-Executive Director Remuneration Cap

Resolution 3 proposes raising the maximum aggregate annual remuneration for non-executive directors by NZ$350,000, increasing the cap from NZ$1,750,000 to NZ$2,100,000 plus GST. This substantial increase requires shareholder approval under New Zealand law and aims to attract and retain high-caliber non-executive directors aligned with market standards and company strategy.

This adjustment excludes the Managing Director and CEO, whose pay is set separately. Shareholders will evaluate whether the higher remuneration cap is appropriate given the company’s scale and complexity. Detailed explanatory notes accompany this resolution for shareholder review.

CEO Lewis Gradon's Long-Term Variable Remuneration Proposal

Resolution 4 seeks approval for granting discretionary long-term variable remuneration instruments to Managing Director and CEO Lewis Gradon. This compensation aligns CEO incentives with long-term shareholder value and is a standard executive pay component. The terms are outlined in the meeting’s explanatory notes.

Shareholder approval reflects governance best practices for significant executive compensation. The package is designed to retain experienced leadership and support strategic goals, with full details available for shareholder consideration.

Introduction of Three New Employee Share Plans for North America

Resolutions 5, 6, and 7 seek approval for three new employee share plans tailored to Fisher & Paykel Healthcare’s North America operations: the 2025 Performance Share Rights Plan, the 2025 Share Option Plan, and the Employee Share Rights Plan. These plans aim to incentivize employees at various levels within the important North American market.

The plans are designed to attract, retain, and motivate talent in this key region. Explanatory notes provide details on plan mechanics, eligibility, and strategic rationale. Shareholders should review documentation to understand potential dilution and alignment with corporate strategy.

Auditor Remuneration and PwC Appointment

Resolution 2 requests shareholder authorisation for the Board to fix fees and expenses payable to PwC as the company’s external auditor. PwC continues in this role, and the resolution is a routine governance step allowing the Board to negotiate auditor fees while maintaining shareholder oversight of the appointment.

This standard practice facilitates audit continuity and fee management. The annual report discloses prior year audit fees, ensuring transparency. Approval supports ongoing audit arrangements with PwC.

Review of Financial Statements for Year Ended 31 March 2026

Shareholders will receive and consider the financial statements and auditor’s report for the fiscal year ending 31 March 2026 as presented in the 2026 annual report. This non-voting agenda item fulfills statutory requirements, with shareholders able to ask questions regarding financial performance and audit during the meeting.

The financial statements provide a detailed overview of the company’s operational and financial results across respiratory care, surgical, and sleep apnea products. Shareholders are encouraged to review the full annual report available at www.fphcare.com/asm. The Chair and CEO will deliver addresses prior to financial statement consideration.

Proxy Voting and Chair’s Voting Intentions

Shareholders unable to attend may appoint proxies, who need not be shareholders themselves. Proxies can be any person, including the meeting Chair. Proxy forms must be submitted online or by post to MUFG Pension & Market Services by 2:00pm NZST on 21 August 2026.

If the Chair, Neville Mitchell, is appointed proxy with discretion to vote, he intends to vote in favor of Resolutions 1, 2, 4, 5, 6, and 7. The Chair plans to abstain on Resolution 3 regarding non-executive director remuneration, reflecting good governance due to potential personal interest. Shareholders should consider these commitments when appointing proxies.

Corporate Structure and Compliance

Fisher & Paykel Healthcare is incorporated in New Zealand (NZBN 9429040719887) and holds an Australian Business Number (ABN 69 098 026 281), reflecting its dual listing on the NZX and ASX (ticker: FPH). Operating across multiple jurisdictions, the company complies with New Zealand and Australian corporate governance and securities laws. The 2026 meeting is conducted under New Zealand Companies Act provisions while addressing ASX investor requirements.

The company’s governance framework, including director elections and remuneration voting, aligns with best practices across both countries. Corporate communications and investor relations teams, led by Karen Knott (GM Corporate Communications) and Dan Adolph (Head of Investor Relations), are available to assist shareholders with meeting inquiries.